Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab.

Patient · 2015 · PMC4383814 · PMID 25736164

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

We also found an improvement in mental health, as evidenced by a highly significant change in the SF-36 MCS score in the siltuximab group as compared with best supportive care.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.